Home >  Investors Relations >  CryoLife Announces Release Date & Teleconference Call Details for 2017 Third Quarter Financial Results

CryoLife Completes Acquisition of JOTEC

December 1, 2017 at 5:04 PM EST

ATLANTA, Dec. 1, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG, a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair. 

Cryolife logo. (PRNewsFoto/CryoLife, Inc.) (PRNewsFoto/CRYOLIFE_ INC_) (PRNewsFoto/CRYOLIFE, INC.)

About CryoLife

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable living tissues used in cardiac and vascular surgical procedures.  CryoLife markets and sells a highly competitive product portfolio focused on treating aortic disease in more than 80 countries worldwide.  For additional information about CryoLife, visit our website, www.cryolife.com.



D. Ashley Lee                                                 

Executive Vice President, Chief Financial Officer and
Chief Operating Officer
Phone: 770-419-3355

The Ruth Group

Zack Kubow



View original content with multimedia:http://www.prnewswire.com/news-releases/cryolife-completes-acquisition-of-jotec-300565402.html

SOURCE CryoLife, Inc.